Osteogenesis Imperfecta Treatment Market

To learn more about this report, Download Free Sample Report

Global Osteogenesis Imperfecta Treatment Market Size

The global osteogenesis imperfecta treatment market was valued at USD 776.10 million in 2025, is estimated to reach USD 794.73 million in 2026, and is projected to reach USD 961 million by 2034, growing at a CAGR of 2.40% from 2026 to 2034.

MARKET DRIVERS

The rising demand for novel therapies for osteogenesis imperfecta treatment is one of the key drivers boosting the growth of the global market. For instance, Mereo Biopharma Group plc.

A clinical-stage firm focusing on developing & commercializing rare illness & oncology therapies, and Oncologic, Inc., an innovative biopharmaceutical company, agreed to a license agreement to develop and commercialize "Navicixizumab" in January 2020. It is a bi-specific anti-DLL4/VEGF antibody used to treat osteogenesis imperfecta.

The strategic acquisitions by the prominent key market players are contributing to the expansion of the global osteogenesis imperfecta treatment market. For instance, the Brittle Bone Disorders Consortium (BBDC) was formed with medical professionals, academics, and researchers in February 2020 to discuss osteogenesis imperfecta. The objective is to create novel, improved therapies for the disorder's patients. The BBDC is researching new disease biomarkers that will help researchers better understand the pathophysiology of osteogenesis imperfecta (OI) and evaluate the effectiveness of treatment. The BBDC also created a patient database and facilitated connections between persons interested in participating in clinical trials, research, and support groups. An essential part of the BBDC mission is its collaboration with the Osteogenesis Imperfecta Foundation and all families affected by OI.

The growing funding actions by the market leaders to conduct research and development around treatment approaches are further propelling the global market growth.

The market for treatments for osteogenesis imperfecta is expanding significantly because of an increase in funding for research and development of novel treatments. There is growing dedication to discovering new treatments for this uncommon genetic condition within the anticipated period. For those with osteogenesis imperfecta, increased investment in innovative therapy offers hope for better results and a higher quality of life. Licensing agreements and collaboration among industry players, the emerging number of OI cases globally owing to family history, and the emerging demand for novel therapies further fuelling the market growth.

MARKET RESTRAINTS

The unavailability of an effective treatment for osteogenesis imperfecta is the major factor hampering the growth of the market. The lack of a truly effective treatment is another major factor hindering global market growth.

There is currently no comprehensive therapeutic alternative for this uncommon genetic condition, which is characterized by weak bones and a high risk of fractures that may ensure a major improvement in patients' lives. Although research and development activities are ongoing, the lack of a proven treatment remains a significant obstacle that limits the market's potential for growth. Innovations in this field are essential to giving people with osteogenesis imperfecta hope and better futures; hence, this factor is majorly hampering the growth of the market during the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS 

By Drug Type Insights

Based on the drug type, the denosumab segment is anticipated to hold the major share of the market during the forecast period. Due to its effectiveness in increasing bone density and lowering fractures, the denosumab segment is projected to grow in the osteogenesis imperfecta treatment market throughout the forecast period. Denosumab, a potent market driver, offers a viable treatment, addressing the unmet requirements of patients with this uncommon genetic condition and promoting segmental expansion.

The teriparatide segment is also anticipated to hold a significant share of the market during the projected period. It is a desirable choice because of its capacity to promote bone formation and enhance bone strength, giving patients and medical professionals who are looking for efficient medicines to treat this difficult condition hope and accelerating segmental growth.

By Route of Administration Insights

Based on the route of administration, the oral segment is expected to grow at a healthy CAGR during the projected period. It is a desirable choice due to its convenience and patient-friendly administration manner, which helps to boost treatment adherence and, in turn, boost segmental growth.

The intravenous segment is also expected to grow at a significant CAGR during the projected period due to its faster onset of action and the ability to reduce the incidence of fracture and increase bone mineral density.

REGIONAL ANALYSIS 

The North American region is anticipated to hold the dominant position in the market during the forecast period due to the rising frequency of osteogenesis imperfecta cases and growing strategic collaboration. For instance, The OI Foundation (OIF) and Children's Brittle Bone Foundation (CBBF) agreed to create and fund a network of interconnected clinical research centers in November 2021. By creating a cooperative network across North America, the objective was to advance treatment and research for OI. The RDCRN (Rare Diseases Clinical Research Network application) was founded on the foundation and framework created by the OIF Linked Clinical Research Centers’ four-year longitudinal investigation of OI.

APAC region is also anticipated to show lucrative growth in the market during the forecast period. During the anticipated period, the APAC region is expected to become a prominent market driver in the osteogenesis imperfecta therapy market. Asia-Pacific is becoming a focus for market expansion and innovation due to developing healthcare infrastructure, a growing patient population, and rising awareness that OI treatments are in high demand.

Europe region is also expected to grow at a healthy CAGR during the projected period. During the anticipated period, the European region will be a key market driver for osteogenesis imperfecta treatments. With a strong healthcare system, innovative study skills, and a dedication to managing rare diseases, Europe is leading the way in developing and implementing novel OI medicines, which is boosting the market share.

Latin America, the Middle East, and Africa are also anticipated to show considerable market growth during the projected period.

KEY MARKET PLAYERS

The prominent key players in the global osteogenesis imperfecta treatment market are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp.

RECENT HAPPENINGS IN THE MARKET

• In October 2022, The Belgian chapter of Osteogenesis Imperfecta Federation Europe (OIFE) was re-established, according to the organization. In Belgium, OIFE is re-established as a new legal entity, whereas it is destroyed in the Netherlands.
• In December 2022, in order to assess the safety, tolerability, and efficacy of a single dosage of SAR439459 in healthy adults with Osteogenesis imperfecta, Sanofi, an innovative global healthcare firm, started a Phase I trial. The FDA has awarded orphan drug designation for this use.
• In July 2023, the first participants in both of Ultragenyx Pharmaceutical Inc.'s late-stage clinical trials evaluating setrusumab in pediatric and young adult patients with OI sub-types I, III, and IV have been dosed, the biopharmaceutical company said. Ultragenyx Pharmaceutical Inc. focuses on the development and commercialization of novel products. In the pivotal Phase 2/3 Orbit research, the annualized clinical fracture rate in patients aged 5 to 26 years is being compared between setrusumab and placebo in the Phase 3 section of the investigation. Setrusumab is being compared to intravenous bisphosphonate (IV-BP) medication on the annualized total fracture rate in patients aged 2 to 5 years in the recently launched Phase 3 Cosmic project, which is an active-controlled study.

MARKET SEGMENTATION

This research report on the global osteogenesis imperfecta treatment market has been segmented and sub-segmented into drug type, route of administration, and region.

By Drug Type

• Teriparatide
• Denosumab
• Others

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa